Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02157051 · ClinicalTrials.gov registry record · Phase 1

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

A Phase 1 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma, sponsored by University of Washington.

Active
Registry status
Phase 1
Development phase
42
Enrollment target
1
Study location

NCT02157051 is a Phase 1 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 42 participants, below the 65-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02157051, a Phase 1 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma, is active but no longer recruiting, sponsored by University of Washington.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and best dose of multiantigen deoxyribonucleic acid (DNA) plasmid-based vaccine in treating patients with human epidermal growth factor receptor 2 (HER2)-negative stage III-IV breast cancer. Multiantigen DNA plasmid-based vaccine may target immunogenic proteins expressed in breast cancer stem cells which are the component of breast cancer that is resistant to chemotherapy and has the ability to spread. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells.

Conditions Studied

Stage IV Breast Cancer Recurrent Breast Carcinoma Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer HER2-Negative Breast Carcinoma Stage III Breast Cancer

Interventions

  • BIOLOGICAL CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
  • OTHER Laboratory Biomarker Analysis

Study Locations (1)

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2015-06
Est. Completion 2026-09-01
Phase Phase 1

Sponsor

University of Washington

1,048 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02157051

The ClinicalTrials.gov registry entry for NCT02157051 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (35% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine is the first listed.

NCT02157051 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT02157051 about?

NCT02157051 is a clinical study titled "Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer". This phase I trial studies the side effects and best dose of multiantigen deoxyribonucleic acid (DNA) plasmid-based vaccine in treating patients with human epidermal growth factor receptor 2 (HER2)-negative stage III-IV breast cancer. Multiantigen DNA plasmid-based vaccine may target immunogenic pro...

What is the current status of trial NCT02157051?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2015-06. Estimated completion is 2026-09-01.

What conditions does trial NCT02157051 study?

This clinical trial studies the following conditions: Stage IV Breast Cancer, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer.

What interventions are being tested in trial NCT02157051?

The interventions under investigation include: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER).

Who is sponsoring clinical trial NCT02157051?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02157051 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IV Breast Cancer

All registered trials for this condition

Recurrent Breast Carcinoma

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.